Biotech Business articles

Recent articles from Biotech Business

OSTEOLOGIX GETS PATENT ALLOWANCE FOR OSTEOPOROSIS DRUG.
July 1, 2009... Osteologix, Inc. (OTCBB:OLGX), has received a Notice of Allowance from the U.S. Patent and Trademark Office for its U.S. Patent Application Number 11/269,289 titled "Water-Soluble Strontium Salts for Use in Treatment of Cartilage and/or Bone Conditions" reporting allowance of claims covering...

SHORT-COURSE RADIOTHERAPY EFFECTIVE FOR BONE METASTASES.
July 1, 2009... A single high dose of radiotherapy is as effective in relieving the pain from vertebral bone metastases as ten smaller treatments according to new research from the Radiation Therapy Oncology Group (RTOG) presented at the American Society of Clinical Oncology Annual Meeting in Orlando. RTOG,...

HPV STATUS PREDICTS SURVIVAL IN OROPHARYNGEAL CANCERS.(Clinical report)
July 1, 2009... The largest and most definitive study to date has found that patients with stage III or IV oropharyngeal cancer (cancers of the upper throat) whose tumors contained the human papillomavirus (HPV) have better outcomes than patients with HPV-negative disease according to new research from the...

ALEXION'S SOLIRIS PREVENTS REJECTION IN KIDNEY TRANSPLANTS.(Clinical report)
July 1, 2009... Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN), Cheshire, Conn., has announced that researchers presented early clinical and laboratory data on the potential role of terminal complement inhibition with Soliris(r) (eculizumab) for the treatment of a subset of kidney transplant patients who are...

SCYNEXIS REPORTS SCY-635 POSITIVE SINGLE AGENT RESULTS.(Financial report)(Clinical report)
June 1, 2009... Drug discovery company SCYNEXIS, Inc., Research Triangle Park, N,C., has presented positive results from a Phase 1b single-agent, randomized, double- blind, placebo-controlled study of its lead, oral, antiviral drug candidate, SCY-635, in adult patients with genotype 1 chronic hepatitis C...